The Limits of Potency: High-Efficacy Therapies and Silent Progression in MS
A large real-world study from the French MS Registry challenges the assumption that high-efficacy therapies (HET) universally outperform moderate-efficacy therapies (MET) in halting all forms of disease progression. Analyzing over 10,000 patients with relapsing-onset multiple sclerosis, researchers found that while HETs were better at controlling disability linked to relapses and new MRI lesions, they showed no significant advantage in preventing “progression independent of relapse and MRI activity” (PIRMA). This silent progression, driven by mechanisms separate from overt inflammatory activity, continued at similar rates regardless of treatment intensity. The findings underscore a critical gap in current therapeutic strategies, highlighting the need for treatments that target the neurodegenerative processes underlying PIRMA.
Why it might matter to you: This research has direct conceptual parallels for rheumatology, particularly in managing autoimmune diseases like rheumatoid arthritis. It reinforces the principle that controlling inflammatory activity (e.g., with potent biologics or JAK inhibitors) may not fully arrest all pathways of tissue damage and long-term disability. For a specialist focused on optimizing disease management, this underscores the importance of composite outcome measures that capture both inflammatory and non-inflammatory progression. It suggests future therapeutic development must look beyond immunosuppression to address the underlying drivers of silent joint erosion and cartilage degeneration.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
